Company Summary - Xenetic Biosciences PLC (LSE:XEN)
10.25p
0.13p
(1.27%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £37.744m
NEW Explore our new and improved report for Xenetic Biosciences PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Development of drug and vaccine delivery systems and proprietary products
| Financials - Interim (24/8/2011) | ||
|---|---|---|
| Turnover | £m | 0.06 |
| Pre-tax Profit | £m | -1.28 |
| EPS | p | -0.72 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Sir Brian Richards | Chairman |
| Colin Hill | Finance Director |
| Scott Maguire | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Lipoxen Technologies Ltd
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Open Offer Update | 01/02/2012 |
| Directorate Change | 27/01/2012 |
| Holding(s) in Company | 27/01/2012 |
For more information
and investor relations, visit the
Xenetic Biosciences PLC company website: